Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone
Summary
Karolinska Development says portfolio company Umecrine Cognition raised SEK 24.6 million through a convertible loan with attached share options. The company will use the proceeds to continue the Phase 1b/2a clinical study of golexanolone in patients with primary biliary cholangitis and to cover operational expenses. The study is recruiting 84 patients across more than 30 sites in eight countries. The company expects to complete the trial in the first half of 2026. Karolinska Development’s ownership will decrease if the loan converts and the share options are fully exercised.
Funding
Amount
$2
Total raised
Date
July 14, 2025
Announcement date
Investors
Karolinska Dev
Lead investors
Company
umecrinecognition.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected